Medivation Inc (MDVN) 81.42 $MDVN Pfizer Announces

New Post Public Reply Private Reply Replies (0) Message Board

Sep 27, 2016 at 5:08 AM

Medivation Inc (MDVN) 81.42 $MDVN

Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation
BusinessWire - Fri Sep 23, 7:30AM CDT
Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer's pending acquisition of Medivation, Inc. (NASDAQ: MDVN).
MDVN: 81.42 (unch), PFE: 33.64 (-0.62)

Shares of MDVN Up 29.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Sep 22, 1:20PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 3 months, Medivation has returned 29.39% as of today's recent price of $81.02.
MDVN: 81.42 (unch)

Forget Novavax, Buy These 4 Biotech Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 2:50PM CDT
Shares of Novavax, Inc. (NVAX) plunged around 82% in pre-market trading on Friday after the biopharmaceutical company announced a day before that its key vaccine candidate unexpectedly failed to meet the primary endpoint in a phase III trial.
QLTI: 1.84 (-0.06), MON: 102.13 (-1.37), PFE: 33.64 (-0.62), VNDA: 17.05 (+0.24), MYL: 41.18 (-0.88), AEGR: 2.65 (-0.10), PDLI: 3.30 (-0.13), MDVN: 81.42 (unch), RPTP: 8.97 (-0.03), S: 6.65 (+0.01), NVAX: 2.35 (+0.09), HZNP: 18.82 (-0.61), EXEL: 15.31 (+0.42)

Zacks.com featured highlights: PTC, Capital Senior Living, ZELTIQ Aesthetics, Conns and Medivation
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:30AM CDT
Zacks.com featured highlights: PTC, Capital Senior Living, ZELTIQ Aesthetics, Conns and Medivation
MDVN: 81.42 (unch), CSU: 16.72 (-0.35), ZLTQ: 39.76 (-0.48), CONN: 10.95 (-0.49), PTC: 43.74 (-0.39)

Research Reports on Biotech Equities -- Galena Biopharma, Mast Therapeutics, Medivation, and Amgen
PR Newswire - Fri Sep 16, 6:35AM CDT
The Biotech industry registered strong gains on Monday, September 12, 2016, with every ETF in the green. Driving stocks higher were surges in M&A deals, dovish comments made by the Fed on policy tightening, and Trump's rising tracking poll results. Today, Stock-Callers.com reviews four equities to see how they fared over the last few trading sessions: Galena Biopharma Inc. (NASDAQ: GALE), Mast Therapeutics Inc. (NYSE MKT: MSTX), Medivation Inc. (NASDAQ: MDVN), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free research reports at: http://stock-callers.com/registration
MDVN: 81.42 (unch), MSTX: 0.12 (-0.01), AMGN: 173.53 (-1.27), GALE: 0.34 (-0.02)

5 Toxic Stocks to Offload or Play Short
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:44AM CDT
Overpricing of toxic stocks can be attributed to either an irrational enthusiasm surrounding them or some serious fundamental drawbacks.
MDVN: 81.42 (unch), CSU: 16.72 (-0.35), ZLTQ: 39.76 (-0.48), CONN: 10.95 (-0.49), PTC: 43.74 (-0.39)

Medivation Has Returned 29.6% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Thu Sep 15, 12:48AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 2 months, Medivation has returned 29.55% as of today's recent price of $81.12.
MDVN: 81.42 (unch)

Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Medivation, Inc.
PR Newswire - Fri Sep 09, 1:09PM CDT
Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California, case no. 3:16-cv-05154, on behalf of shareholders of Medivation, Inc. ("Medivation" or the "Company"

(NasdaqGS:MDVN) who held Medivation securities and have been harmed by Medivation's and its board of directors' (the "Board"

alleged violations of Sections 14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"

and SEC Rule 14d-9 in connection with the proposed acquisition ("Proposed Transaction"

of the Company by Pfizer, Inc.(" Pfizer"

.
MDVN: 81.42 (unch)

Medivation (MDVN) Scales New 52-Week High on Pfizer Deal
Zacks Equity Research - Zacks Investment Research - Fri Sep 09, 9:25AM CDT
Shares of Medivation, Inc. (MDVN) hit a 52-week high of $80.99 on Thursday, Sep 9.
MDVN: 81.42 (unch), PFE: 33.64 (-0.62), ANIK: 45.82 (-1.10), SNY: 38.04 (-0.31)

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Medivation, Inc. (MDVN)
GlobeNewswire - Thu Sep 08, 4:56PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Medivation, Inc. ("Medivation" or the "Company"

(Nasdaq:MDVN) in the United States District Court for the Northern District of California on behalf of current stock holders of Medivation, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act"

.
MDVN: 81.42 (unch), JPM: 65.78 (-1.47), PFE: 33.64 (-0.62)

Medivation Up 29.0% Since SmarTrend Uptrend Call (MDVN)
Comtex SmarTrend(R) - Wed Sep 07, 1:50PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 2 months, Medivation has returned 29.01% as of today's recent price of $80.78.
MDVN: 81.42 (unch)

MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc.
PR Newswire - Tue Sep 06, 3:49PM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medivation, Inc. ("Medivation" or the "Company"

(NasdaqGS:MDVN) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $14 billion.
MDVN: 81.42 (unch), PFE: 33.64 (-0.62)

Drug Stocks Remain in Focus as Pricing Debate Continues
Arpita Dutt - Zacks Investment Research - Mon Sep 05, 7:38AM CDT
Mylan (MYL) finds itself in troubled waters with lawmakers now questioning Medicaid rebates for EpiPen.
MDVN: 81.42 (unch), VRX: 25.89 (-1.83), VRTX: 88.29 (-2.34), GILD: 80.62 (-0.75), MYL: 41.18 (-0.88)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc.
BusinessWire - Fri Sep 02, 10:10AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc. ("Medivation" or "the Company"

(Nasdaq: MDVN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer"

.
MDVN: 81.42 (unch), PFE: 33.64 (-0.62)

Uptrend Call Working As Medivation Stock Rises 28.3% (MDVN)
Comtex SmarTrend(R) - Wed Aug 31, 1:06AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 2 months, Medivation has returned 28.34% as of today's recent price of $80.36.
MDVN: 81.42 (unch)

Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 81.42 (unch), JNJ: 117.78 (-1.03), GE: 29.54 (-0.35), GS: 161.48 (-3.65), PFE: 33.64 (-0.62), AZN: 33.55 (-0.42), MYL: 41.18 (-0.88), BWXT: 38.76 (-0.16), BA: 130.57 (-1.21), VZ: 52.15 (-0.41), MS: 31.03 (-0.88)

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BusinessWire - Thu Aug 25, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Medivation, Inc. (NASDAQ: MDVN) ("Medivation" or the "Company"

relating to the proposed buyout of Medivation by Pfizer Inc.
MDVN: 81.42 (unch), PFE: 33.64 (-0.62)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders
BusinessWire - Thu Aug 25, 1:50PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
MDVN: 81.42 (unch), PFE: 33.64 (-0.62)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Millrose Properties Faces Class Action Deadline Amid Turmoil

Millrose Properties: Legal Storm Brewing If you've got stock in Millrose Properties, Inc. (NYSE:MRP), you might want to listen up. There's a class action lawsuit in the works that could have quite the impact. Investors have until December 8, 2026, to throw their hat in the ring and maybe even lead the charge on this lawsuit. The Allegations Up Close Let's break down what...

Valve Tool Innovation Streamlines Hydraulic Maintenance

A New Gadget Promises Big Savings in Time and Effort Ever wrestled with a hydraulic hose and felt like you were arm wrestling a gorilla? Well, it looks like there's a new gadget on the scene that might save you from that struggle. Straight from Menomonie, Wisconsin, we’ve got a slick new tool hitting the market called THE VALVE TOOL. The idea is simple but effective:...

Inside Kristallnacht: An XR Journey for a New World

Bridging the Past with Powerful Tech: A Journey to Kristallnacht Let's cut to the chase: if there's a time in history that we all need to sear into our collective consciousness, it's Kristallnacht. Forget the mere notion of reading it from a textbook; now you can dive headfirst into the harrowing events of November 9, 1938, thanks to the cutting-edge initiative inside...

Moore County Relocation: Key Tips for Newcomers

Understanding the Moore County Landscape Take a moment to picture Moore County, NC—more than just a dot on your digital maps. This place has a lot more going on beneath the surface for out-of-state buyers looking to set down roots. I'm talking about a mix of geography, lifestyle, and practicalities that won't show up in your online browsing sessions. More Than Meets the...

Orthodontic Treatment: Timelines and Expert Insights

Getting Straight to the Point: Orthodontic Timelines Remember that time your teen self thought braces would be over in a flash? Yeah, well, Dr. Judith Okun might have a few words on that. When it comes to braces, you better buckle up for the long haul. Most folks are looking at a solid two years, give or take. No magic shortcuts here, just solid orthodontic science. The...

FSBO.com Boosts Real Estate Game with New Apps

FSBO.com Bets Big on Mobile With New App Launch FSBO.com has unleashed something that might just shake up how we think about buying and selling homes. They're not just rolling out apps—they're weaving another layer onto the fabric of real estate itself. While other players tossed their hats into the app game long ago, FSBO.com is kicking it up a notch with their new iOS...

NextVision's Q3 2026: Impressive Growth and Expansion

NextVision's financials this quarter are the envy of tech growth companies everywhere. Their Q3 2026 report reads like a thrilling playbook for success. No half-measures here—NextVision has doubled its revenue, slashed costs, and cooked up an operating margin fit for a kingpin. Pushing Revenue to New Heights NextVision didn’t just surpass last year's revenue; it...

Biond's BND-67 Trial: New Hope Against Tumors

Turning Heads with a New Approach in Immunotherapy Right off the bat, let's say something's brewing in the world of cancer treatment, and it's got a promising name: BND-67. We're talking about Biond Biologics, an ambitious Israeli outfit aiming to rewrite the rules with their new kid on the block in immunotherapies. This isn't about business as usual. It's about a fresh...

Nevada Organic Phosphate Plans Share Consolidation

The Drill Down on Nevada Organic Phosphate's Strategic Moves There's a lot to unpack here as Nevada Organic Phosphate Inc. (CSE: NOP) rolls out its big game plan. They're looking to consolidate shares, flex their financial muscles, and maybe spray some high-octane fuel on their market positioning. Could be a smart move if they pull it off, but that's a big 'if' hanging in...

PVA Unveils Hotel Accessibility Guide for Disabled Travelers

Is Your Hotel Truly Accessible? Time to Find Out. Another day, another step toward making the world a bit more navigable for folks with mobility challenges—and it's about time the hospitality sector caught up. Today, Paralyzed Veterans of America (PVA) rolled out the first volume of their 'Best Practices in Hotel Accessibility Guide.' Think of it as a roadmap for hotels...